GSE111061 tofacitinib 1 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE111061_tofacitinib_1_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE111061_tofacitinib_1_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE111061_tofacitinib_1_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE111061_tofacitinib_1_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

DUS4L-BCAP29 readthrough

Gene

ZNF710 antisense RNA 1

Gene

ACTA2 antisense RNA 1

Gene

long intergenic non-protein coding RNA 1315

Gene

ZSCAN16 antisense RNA 1

Gene

DEAD/H-box helicase 11 like 2 (pseudogene)

Gene

ring finger protein-like

Gene

Tu translation elongation factor, mitochondrial pseudogene 1

Gene

ribosomal protein SA pseudogene 70

Gene

KBTBD11 overlapping transcript 1

  • Gene

    DUS4L-BCAP29 readthrough


  • Gene

    ZNF710 antisense RNA 1


  • Gene

    ACTA2 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1315


  • Gene

    ZSCAN16 antisense RNA 1


  • Gene

    DEAD/H-box helicase 11 like 2 (pseudogene)


  • Gene

    ring finger protein-like


  • Gene

    Tu translation elongation factor, mitochondrial pseudogene 1


  • Gene

    ribosomal protein SA pseudogene 70


  • Gene

    KBTBD11 overlapping transcript 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.